Silo Pharma Takes Next Step in Bringing Homing Peptide Tech to $30+ Billion RA Market
July 23rd, 2021
Psychedelics, Top Story, Uncategorized
Rheumatoid arthritis, or RA, is an autoimmune and inflammatory disease that causes painful swelling in joints in the hands, wrists, and knees. While medications can slow the disease and prevent joint deformity, there is no cure for the condition, and many millions still suffer from it.
Silo Pharma Inc. (OTCQB: SILO) is a development-stage biopharmaceutical company leveraging homing peptides to improve cellular targeting. In RA, the company hopes to deliver dexamethasone via peptide-guided liposomes to enhance its efficacy and toxicity profile.
Let’s take a look at the company’s recent move toward commercialization, as well as how its underlying technology could pave the way for expansion into other markets.
Moving Toward Commercialization
Silo Pharma extended its exclusive option agreement with the University of Maryland-Baltimore earlier this month to explore a novel intervention, generally known as “joint-homing peptides for use in the investigation and treatment of arthritogenic processes,” which has shown a lot of promise in early-stage research in targeting specific cells.
The company subsequently entered into a Scientific Research Agreement with the university to evaluate the pharmacokinetics of dexamethasone delivered to arthritic rats via its peptide-guided liposomes. By selecting an FDA-approved drug, the researchers can focus on delivering the maximum possible dose to specific areas.
“This agreement is a milestone for the company as we add a significant addressable market for our therapeutic approach,” said Chairman and CEO Eric Weisblum in a press release. “This study will … help establish our hypothesis that we can not only target parts of the body but can lower toxicity and help keep healthy organs unexposed to therapeutics.”
Expansion into Psychedelics
Silo Pharma believes that the same peptide-guided liposomes are adaptable to other drugs because liposomes can be loaded with both hydrophobic and hydrophilic drugs, permitting combination drug therapies. These drugs include emerging psychedelic medicines, such as ketamine and psilocybin for mental health conditions.
In addition to their work with the University of Maryland-Baltimore, the company is working with the University of California-San Francisco via a Scientific Research Agreement to study psilocybin as an anti-inflammatory agent in Parkinson’s disease and bipolar disorder. The study is taking place via the Translational Psychedelic Research Program.
The company is also waiting on a Netherlands-based investigator-led study of psilocybin to treat Parkinson’s disease, submitted for ethics board review in May, and entered into a joint venture with Zylo Therapeutics to develop a transdermal ketamine therapeutic, among other efforts in the psychedelics space.
Silo Pharma Inc. (OTCQB: SILO) has made significant progress in advancing its homing peptide-based technology into rheumatoid arthritis and other markets. Leveraging the same technology platform, the company hopes to target a wide range of different drugs, enabling more efficacy and an improved patient safety profile.
The company also continues to build and monetize its intellectual property through licensing agreements, such as its agreement with Alkido Pharma Inc. (NASDAQ: AIKI) earlier this year. Under these agreements, the company could receive upfront cash payments and ongoing royalty payments on products developed with the technology.
For more information about Silo Pharma, visit the company’s website or download their investor presentation.
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.